The pharmaceutical industry is experiencing a important shift in glucose care with the emergence of GLP-1 transdermal devices. These groundbreaking delivery systems offer a potentially convenient alternative to subcutaneous injections for individuals living with diabetes. By circumventing the need for frequent needles, GLP-1 skin devices promise to